Table 1.
HCV screening outcomes by cohort at an urban safety-net health system in Chicago, Illinois, February 1, 2017–January 31, 2019a
| Screening outcome | Total | Cohortb (n = 6597) | Noncohortc (n = 14 421) | P value |
|---|---|---|---|---|
| Tests | ||||
| HCV antibody tests | 21 018 | 6597/21 018 (31%) | 14421/21 018 (69%) | <.001d |
| Positive test result for HCV antibody | 1318 | 874/1318 (66%) | 444/1318 (34%) | <.001d |
| Positive test results for HCV antibody with sample reflexed for RNA teste | 1293 | 857 (—) | 436 (—) | — |
| Positive result for HCV RNA | 878 | 599/878 (68%) | 279/878 (32%) | <.001d |
| Positivity rates | ||||
| Anti-HCV positivityf | 1318/21 018 (6%) | 874/6597 (13%) | 444/14 421 (3%) | <.001g |
| RNA anti-HCV positivityh | 878/1293 (68%) | 599/857 (70%) | 279/436 (64%) | .04g |
| RNA positivityi | 878/21 018 (4%) | 599/6597 (9%) | 279/14 421 (2%) | <.001g |
Abbreviations: —, does not apply; anti-HCV, HCV antibody; HCV, hepatitis C virus.
aData collected from health system records.
bPeople born during 1945-1965.
cPeople born outside the cohort.
dOne-sample t test of proportions for difference between cohort and noncohort; P < .05 considered significant.
eTwenty-five samples insufficient for reflex to detect HCV RNA.
fNumber of positive HCV antibody test results divided by number of HCV antibody tests.
gPearson χ2 test of independence for difference between cohort and noncohort; P < .05 considered significant.
hNumber of positive RNA test results divided by number of positive HCV antibody test results with sample reflexed for HCV RNA.
iNumber of positive RNA test results divided by total number of HCV antibody tests.